ClinicalTrials.gg
RecruitingNCT07496255Updated Apr 17, 2026

Virtual Reality Cognitive Intervention for Critically Ill Delirium Survivors (VR-Cog)

An interventional study of VR-based cognitive training program and VR-based attention control in Intensive Care Unit Delirium, Intensive Care Acquired Cognitive Impairment and Post Intensive Care Unit Syndrome, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cognitive Dysfunction by Indiana University — 6 open to participants now, 8 under way, none of them phase 3. Cognitive Dysfunction · Indiana University.

Planned enrollment
13th of 20
100 · median 143
Started
2026
the only one that year
No phase
17 of 23
6 open now
Registered
22nd of 23
by date

Among the 23 studies in Cognitive Dysfunction by Indiana University, this one is the 13th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, and was the 22nd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

6 of the 23 studies in Cognitive Dysfunction by Indiana University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cognitive Dysfunction by Indiana University, or all of them as a file.
02

Study summary

The purpose of this study is to measure the feasibility, acceptability of virtual reality (VR) brain games and estimate their effect on memory, attention, and mood for ICU survivors. The VR program will be used at home through a headset and hand controls.

Read the detailed description

Acute respiratory failure (ARF) accounts for 2 million admissions to adult intensive care units (ICUs) in the United States annually, and up to 80% of older adults with ARF suffer delirium, a form of ICU-related acute brain dysfunction. Delirium doubles the risk for new cognitive impairment or dementia within 12 months of ICU discharge. In addition, delirium survivors frequently develop related mental health and quality of life impairments. Unfortunately, there are few effective or scalable interventions to improve cognitive outcomes for ICU survivors.

Primary Objective Aim 1: Measure the feasibility, acceptability, and adherence of VR-Cog in older adult ICU delirium survivors at risk for ICU-acquired MCI and ADRD.

Secondary Objective Aim 2: Estimate the effect of VR-Cog on cognitive performance among older adult ICU delirium survivors.

Tertiary/Exploratory/Correlative Objectives Aim 3: Explore the effects of VR-Cog on mental health (depression and anxiety).

03

Conditions studied

  • Intensive Care Unit Delirium
  • Intensive Care Acquired Cognitive Impairment
  • Post Intensive Care Unit Syndrome
  • Virtual Reality Cognitive Training
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 50 years or older
  • English speaking
  • Admitted to the intensive care unit (ICU) with acute respiratory failure/invasive mechanical ventilation
  • Screening positive for delirium (using Richmond Agitation Sedation Scale and Confusion Assessment Method for the ICU)

Exclusion criteria

Exclusion Criteria:

  • Acute neurologic injury such as stroke, traumatic brain injury, brain mass, intracranial hemorrhage, seizures, or central nervous system infection
  • Chronic cognitive or physical function deficit preventing participation in study interventions or assessments (determined by chart diagnoses and direct participant interview)
  • Chronic cognitive impairment (including mild cognitive impairment or dementia) identified by chart diagnosis, prescription of anti-dementia medications, or Informant Questionnaire on Cognitive Decline in the Elderly Score (IQCODE) >3.3 obtained from family caregiver
  • Severe, uncorrected vision or hearing impairment preventing participation in intervention or outcomes assessments
  • Admitted with acute alcohol or drug intoxication or withdrawal
  • Severe, uncontrolled psychiatric disorder (bipolar disorder or schizophrenia)
  • History of severe vertigo, motion-induced sickness, headaches, light sensitivity, seizures, or prior intolerance of virtual reality (VR)
  • Receiving comfort care measures or not expected to survive the hospitalization
  • Prisoners or patients unable to provide consent
  • Not expected to be discharged home from the hospital, or living more than 50 miles from the nearest recruitment site, or homeless
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    VR-based cognitive training program

    Device: VR-based cognitive training program

  • Placebo comparator
    VR-based attention control

    Device: VR-based attention control

Interventions

  • DeviceVR-based cognitive training program

    VR-Cog features HomeTown Bound, a suite of 18 modules organized into four training categories: attention, processing speed, memory, and visuospatial.

    Also known as: VR-Cog

  • DeviceVR-based attention control

    VR-AC consists of a library of 9 nature scenes (content provided by Nature Treks VR).

    Also known as: VR-AC

06

What researchers measure

Primary outcomes

  1. Measure the feasibility of VR-Cog in older adult ICU delirium survivors

    Feasibility will be measured by the percentage (%) of intervention sessions delivered to participants, with greater than or equal to 80% of intervention sessions completed defining feasibility.

    Time frame: Feasibility will be measured at 4 weeks (the end of the intervention period)

  2. Measure the acceptability of VR-Cog in older adult ICU delirium survivors

    Acceptability will be defined as scores of 8 or greater on each subscale of the Senior Technology Acceptance Model (STAM, Short Form with 14-items). The four subscales of the STAM measure attitudes towards technology (perceived use and effectiveness), control beliefs (ability to use the technology and complete tasks), gerontologic anxiety (feeling apprehensive or hesitant with technology applications), and general health (ability to concentrate, satisfaction with general health).

    Time frame: Acceptability will be measured at 4 weeks (the end of the intervention period)

  3. Measure the adherence to VR-Cog in older adult ICU delirium survivors

    Adherence to the protocol will be assessed through rates of retention at end of 4-week intervention (80% among participants alive and out of the hospital) and completion of outcomes assessments (80% among participants alive and out of the hospital).

    Time frame: Adherence will be measured at 4 weeks (the end of the intervention period)

Secondary outcomes

  1. Estimate the effect of VR-Cog on cognitive performance among older adult ICU delirium survivors.

    Repeatable Battery for Assessment of Neuropsychological Status (RBANS)

    Time frame: Measured at Baseline, 4 weeks (end of intervention period), 3-Month and 6-Month follow up

  2. Explore the effects of VR-Cog on depression

    As measured by Patient Health Questionnaire (PHQ-9)

    Time frame: Measured at baseline (hospital discharge), 4 weeks (end of intervention period), 3-months and 6-months post-randomization.

  3. Explore the effects of VR-Cog on anxiety

    As measured by Generalized Anxiety Disorder (GAD-7) scale

    Time frame: Measured at baseline (hospital discharge), 4 weeks (end of intervention period), 3-months and 6-months post-randomization.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 10 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 27, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Feb 15, 2027
CompletionEst.
Jul 15, 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07496255
Lead sponsor
Indiana University
Collaborators
Indiana University Health
Responsible party
Sikandar Khan (Assistant Professor of Medicine, Indiana University) — Principal investigator
First posted
Mar 27, 2026
Start date
Mar 19, 2026
Primary completion
Feb 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Apr 17, 2026

Study contacts

Sikandar Khan, DO, MS
Contact
sikhan@iu.edu
(317) 274-9427
Lori Rawlings, RN, BSN
Contact
rawlingl@regenstrief.org
317-274-9052
Sikandar Khan, DO, MS
principal investigator · Indiana University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion